Last updated: January 30, 2024
Sponsor: QuantuMDx Group Ltd
Overall Status: Completed
Phase
N/A
Condition
Covid-19
Treatment
RT-PCR Test
Real-time PCR Test
Clinical Study ID
NCT05614011
QVTP-39
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Participants must be over the age of 18 years.
- Participants must present with symptoms indicative of SARS-CoV-2 infection, within 0-5days of symptom onset.
- Participants must have capacity to give informed consent.
Exclusion
Exclusion Criteria:
- Participant is under the age of 18 years.
- Participant does not have symptoms of SARS-CoV-2 infection.
- Participant lacks capacity to give informed consent.
Study Design
Total Participants: 877
Treatment Group(s): 2
Primary Treatment: RT-PCR Test
Phase:
Study Start date:
November 28, 2022
Estimated Completion Date:
May 17, 2023
Study Description
Connect with a study center
Paragon Rx Clinical, Inc.
Santa Ana, California 92703
United StatesSite Not Available
Bright Research Center
Miami, Florida 33144
United StatesSite Not Available
EDP Biotech
Knoxville, Tennessee 37919
United StatesSite Not Available
PathAI
Memphis, Tennessee 38125
United StatesSite Not Available
PRX Research and Development, LLC DBA PRX Research
Mesquite, Texas 75149
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.